NextGenGENERATION 02 / TWO TARGETS
Compounded tirzepatide, in plain words.
This page separates tirzepatide’s two-target design from the status of a compounded medicine, made to order. Products approved by the U.S. Food and Drug Administration (FDA) exist. Compounded tirzepatide is not FDA-approved. A licensed provider decides whether a medicine is appropriate.
TARGET STUDY / 02
GIP + GLP-1
01
One compound. Two kinds of signal.
Tirzepatide is a peptide, a short chain of protein building blocks. It is a dual agonist: a compound that activates two receptor types. A receptor is a part of a cell that receives a signal.
Its targets are GIP and GLP-1. Both names refer to hormone signals. Hormones carry messages in the body. These initials help explain tirzepatide's design, but they do not tell a reader whether it is suitable for them.
In our generations guide, semaglutide has one target, tirzepatide has two, and investigational retatrutide has three. The count is a description. It is not a personal treatment plan.
02
The ingredient name is only part of the story.
A licensed pharmacy and an approved product are separate things. A pharmacy's licence does not give FDA approval to the medicine it compounds.
The law limits routine copies of medicines already available. A provider must consider the patient's needs and the legal limits. The word compounded does not, by itself, settle those questions.
FDA-approved product
The U.S. Food and Drug Administration has reviewed a specific finished medicine. FDA-approved products containing tirzepatide exist.
Compounded medicine
Compounding means making a medicine to order. Compounded tirzepatide is not FDA-approved. The FDA does not review its safety, quality or effectiveness before it is sold.
03
The review is about a person.
A provider's review can include medical history, other medicines and pregnancy plans. Tirzepatide's approved product information includes warnings that make those details relevant. A product name cannot replace that review.
Questions for that conversation include: Which exact medicine is being considered? What is its approval status? Is it made to order? Which pharmacy would be involved? What follow-up would the provider arrange?
This page describes the questions. It does not choose a medicine, give instructions for using one, or decide whether anyone qualifies.
04
A research order has a different purpose.
An online product marked “not for human use” is not a prescription route. No one reviews your health as part of that research-only purchase. The FDA has warned about unapproved tirzepatide sold under research labels and about unknown product quality.
05
The linked U.S. route starts with review.
Promise prescribes semaglutide and tirzepatide now through licensed U.S. providers. A provider reviews every request and decides whether to prescribe. Not everyone qualifies.
A licensed U.S. provider reviews each request and makes the prescription decision. A product choice does not guarantee a prescription.
Medications are prepared by licensed U.S. compounding pharmacies. Compounded medications are not FDA-approved.
Promise is for U.S. patients only. Availability varies by state and by treatment.
Promise is LegitScript-certified. This is a private check of business standards, not FDA approval or a rating of medical care.
06
Reading behind this page.
- Tirzepatide: approved product information
Records the GIP and GLP-1 targets and the status of a specific approved tirzepatide product.
- FDA: what compounding means
Explains medicines made to order and how they differ from FDA-approved products.
- FDA: concerns about unapproved GLP-1 drugs
Covers unapproved products, including retatrutide, sold with research-only labels.
Keep the review in the picture.
Promise prescribes semaglutide and tirzepatide now through licensed U.S. providers. A provider reviews every request and decides whether to prescribe. Not everyone qualifies.